North America
South America
Australia & New Zealand
Europe
Middle East / Africa
Asia / Pacific
×
×
FITC Mouse Anti-Human CD30 Ber-H83 RUO (GMP)

FITC Mouse Anti-Human CD30 

Clone  Ber-H83   (RUO (GMP))

  • Concentration 3 µg/mL
  • Vol. Per Test 20 μL
  • Isotype Mouse BALB/c IgG1, κ
  • Reactivity Human (QC Testing) 
  • Application Flow cytometry (Routinely Tested) 
  • Immunogen Co Cells
  • Entrez Gene ID 943 
  • Storage Buffer Phosphate buffered saline with gelatin and 0.1% sodium azide.
  • Regulatory Status RUO (GMP)
Product Details Recommended Assay References

Description

CD30, clone Ber-H83, is derived from the hybridization of mouse NS-1 myeloma cells with spleen cells from BALB/c mice immunized with Co cells.

CD30 recognizes a 120-kilodalton (kd) type I transmembrane glycoprotein. The CD30 antigen belongs to the tumor necrosis factor receptor/nerve growth factor receptor (TNFR/NGFR) superfamily.

Format
  • Format FITC
  • Excitation Source Blue 488 nm
  • Excitation Max 494 nm
  • Emission Max 520 nm

FITC, fluorescein isothiocyanate, is a fluorochrome with a molecular weight of 389 Da. FITC is sensitive to pH changes and photobleaching. Due to nearly identical excitation and emission properties but different spillover characteristics, FITC and Alexa Fluor® 488 cannot be used simultaneously. FITC is relatively dim and should be reserved for highly expressed markers whenever possible.

Other Formats →

Resources & Tools
 Spectrum Viewer  Panel Designer  Spectrum Viewer  Download TDS  Regulatory Document Website
Preparation and Storage

The FITC and PE conjugates are each supplied as 3 μg in 1.0 mL (3 μg/mL) of phosphate-buffered saline (PBS). PBS contains gelatin and 0.1% sodium azide. Store vials at 2° to 8°C. Conjugated forms should not be frozen and should be protected from prolonged exposure to light. Each reagent is stable for the period shown on the bottle label when stored as directed.


  1. Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ, Inghirami G. Molecule of the month: CD30 in normal and neoplastic cells. Clin Immunol. 1999;90:157-164.

  2. Dürkop H, Latza U, H S. Overview of CD30. In: Schlossman SF, Boumsell L, Gilks W, et al, eds. Leucocyte Typing V: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1995:1115-1116.

  3. Jones DB, Cantarini M, Higginson K, Wright DH. Identification of antibodies in the Workshop activation panel reactive with tumour cells in Hodgkin's disease. In: Knapp W, Dörken B, Gilks WR, et al, eds. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1989:478-479.

  4. Schwarting R, Stein H. Cluster report: CD30. In: Knapp W, Dörken B, Gilks WR, et al, eds. Leucocyte Typing IV: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1989:419-421.

  5. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66:848-858.

341644 Rev.
Instruments
Reagents
Applications
Sales & Support
BD BioSciences